irsogladine has been researched along with Infections, Helicobacter in 3 studies
irsogladine: RN given refers to parent cpd; MN 1695 refers to maleate salt
| Excerpt | Relevance | Reference |
|---|---|---|
| " pylori-positive gastric ulcer were given eradication treatment, then assigned randomly to a treatment group [given 4 mg/day irsogladine maleate (n = 150)] or a control group [given a placebo (n = 161)]." | 9.14 | Clinical trial: irsogladine maleate, a mucosal protective drug, accelerates gastric ulcer healing after treatment for eradication of Helicobacter pylori infection--the results of a multicentre, double-blind, randomized clinical trial (IMPACT study). ( Goto, H; Haruma, K; Hiraishi, H; Miwa, H, 2010) |
| "Irsogladine has previously been shown to accelerate the healing of gastric ulcers after H." | 6.76 | Comparison of the efficacy of irsogladine maleate and famotidine for the healing of gastric ulcers after Helicobacter pylori eradication therapy: a randomized, controlled, prospective study. ( Abe, H; Arita, T; Fujioka, T; Kodama, M; Mizukami, K; Murakami, K; Okimoto, T; Shuto, M; Tanahashi, J, 2011) |
| " pylori-positive gastric ulcer were given eradication treatment, then assigned randomly to a treatment group [given 4 mg/day irsogladine maleate (n = 150)] or a control group [given a placebo (n = 161)]." | 5.14 | Clinical trial: irsogladine maleate, a mucosal protective drug, accelerates gastric ulcer healing after treatment for eradication of Helicobacter pylori infection--the results of a multicentre, double-blind, randomized clinical trial (IMPACT study). ( Goto, H; Haruma, K; Hiraishi, H; Miwa, H, 2010) |
| "Irsogladine, a mucosal protective drug, was developed in Japan for the treatment of peptic ulcer disease and acute gastritis." | 4.89 | Irsogladine: overview of the mechanisms of mucosal protective and healing- promoting actions in the gastrointestinal tract. ( Akagi, M; Amagase, K; Murakami, T; Takeuchi, K, 2013) |
| "Irsogladine has previously been shown to accelerate the healing of gastric ulcers after H." | 2.76 | Comparison of the efficacy of irsogladine maleate and famotidine for the healing of gastric ulcers after Helicobacter pylori eradication therapy: a randomized, controlled, prospective study. ( Abe, H; Arita, T; Fujioka, T; Kodama, M; Mizukami, K; Murakami, K; Okimoto, T; Shuto, M; Tanahashi, J, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hiraishi, H | 1 |
| Haruma, K | 1 |
| Miwa, H | 1 |
| Goto, H | 1 |
| Murakami, K | 1 |
| Okimoto, T | 1 |
| Kodama, M | 1 |
| Tanahashi, J | 1 |
| Mizukami, K | 1 |
| Shuto, M | 1 |
| Abe, H | 1 |
| Arita, T | 1 |
| Fujioka, T | 1 |
| Akagi, M | 1 |
| Amagase, K | 1 |
| Murakami, T | 1 |
| Takeuchi, K | 1 |
1 review available for irsogladine and Infections, Helicobacter
| Article | Year |
|---|---|
Irsogladine: overview of the mechanisms of mucosal protective and healing- promoting actions in the gastrointestinal tract.
Topics: Animals; Anti-Ulcer Agents; Gastric Mucosa; Gastritis; Gastrointestinal Diseases; Helicobacter Infec | 2013 |
2 trials available for irsogladine and Infections, Helicobacter
| Article | Year |
|---|---|
Clinical trial: irsogladine maleate, a mucosal protective drug, accelerates gastric ulcer healing after treatment for eradication of Helicobacter pylori infection--the results of a multicentre, double-blind, randomized clinical trial (IMPACT study).
Topics: Adult; Anti-Ulcer Agents; Double-Blind Method; Female; Helicobacter Infections; Helicobacter pylori; | 2010 |
Comparison of the efficacy of irsogladine maleate and famotidine for the healing of gastric ulcers after Helicobacter pylori eradication therapy: a randomized, controlled, prospective study.
Topics: Aged; Alcohol Drinking; Anti-Ulcer Agents; Drug Administration Schedule; Famotidine; Female; Helicob | 2011 |